Navigation Links
CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
Date:3/5/2008

s. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be used by health care professionals qualified by training and experience in the safe use of radionuclides.

Patients and healthcare professionals can visit http://www.zevalin.com for more information.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of Zevalin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with Zevalin in particular including, without limitation, the potential failure of Zevalin to prove safe and effective in further studies in combination with CHOP for first-line treatment of elderly patients with diffuse large B-cell lymphoma or to be developed further in this combination for this indication, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of d
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
2. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
3. New Drug Application for Tolvaptan, Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
4. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
5. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
8. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
9. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
10. Tom Shaws NFL Training Center Chooses SURGEX(TM) as Their Exclusive Post Training Nutritional Regimen
11. Anthrax vaccine produces immunity with nanoparticles, not needles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... , May 26, 2015   PDI ... solutions, today announced that Oakwood Healthcare in ... as the winning entry in Delivering ... professionals who display excellence in building collaborative relationships ... teams in healthcare facilities.  Oakwood ...
(Date:5/26/2015)... Kevin Xu , prezident MEBO ... Obamovi a Billovi Clintonovi za ich kondolencie a ... Rongxiang Xu , otca Kevina. ... Xu bol pionier, inovátor, humanitárny pracovník a vodca ... vedy a príkladné vedenie svojej komunity zanecháva odkaz, ...
(Date:5/26/2015)... - Fluorinov Pharma (Fluorinov), a FACIT portfolio company, today ... to its Board of Directors.  His appointment strengthens Fluorinov,s ... Fluorinov accelerates its clinical development activities.  ... pleasure to welcome Luke to the Board of Directors.  ... financial strength and success of multiple organizations," said ...
(Date:5/26/2015)... Just the characterization of being a new ... does not guarantee immediate acceptance. In particular, a ... prior failures is often met with significant skepticism. ... irony that is often an unappreciated aspect of scientific ... Asymmetrex has found that building acceptance of its ...
Breaking Biology Technology:PDI Announces Winner in Delivering the Difference Contest 2PDI Announces Winner in Delivering the Difference Contest 3Dr. Rongxiang Xu, O legende 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 3In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 2In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 3
... Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ), a ... product candidates principally,for use in the hospital setting, ... Schroeder will present the company,s corporate,overview at the ... 33rd Annual Healthcare Conference at the ...
... Bristol-Myers Squibb,Company (NYSE: BMY ) invites investors ... its annual meeting with stockholders at 10 a.m. ET ... and board items to be,transacted, senior executives will review ... how to listen to the webcast, please visit the,Investor ...
... from Adaptive Business Leaders (ABL) Organization Recognizes ... Transformative Advances in Healthcare, SUNNYVALE, Calif., April 30 ... in the field of radiosurgery,today announced that the company ... Business Leaders (ABL) Organization in the,"Innovations in Medical/Diagnostics Technology" ...
Cached Biology Technology:Cadence Pharmaceuticals' CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008 2Accuray Wins Innovations in Healthcare(SM) ABBY Award 2Accuray Wins Innovations in Healthcare(SM) ABBY Award 3Accuray Wins Innovations in Healthcare(SM) ABBY Award 4
(Date:5/11/2015)... May 11, 2015  Through a well-rounded UAS delegation representing ... had a strong showing at AUVSI,s Unmanned 2015 conference last ... Ohio,s UAS industry met with over ... all points along the UAS ecosystem. "Our ... Vice President for Aerospace Rich Knoll . "If you ...
(Date:5/6/2015)... May 6, 2015 LifeBEAM, a developer of ... producer, announced today that they will expand their partnership ... first bio-sensing cycling helmet and the first joint project ... new colors in order to give cyclists more style ... addition, LifeBEAM and Lazer announced their plan to release ...
(Date:4/21/2015)... BURNABY, Canada , April 21, 2015 ... spending and evolving government policies are boosting access control ...   According to a recently published report ... & Opportunities, 2020 ", the access control systems market ... to nearly USD1.2 billion by 2020.The access control systems ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3
... that certain countries and some U.S. states stand to benefit ... in the fight against global warming. Some places may even ... to compact fluorescent lighting. The study, which appears ... Technology , looked at all 50 states and 130 countries ...
... in the October 2008 issue of BioScience are as ... with a Molecular Master. Kabir G. Peay, ... techniques have in recent years allowed the systematic exploration ... extremely high diversity and variability of fungi in natural ...
... When a cell,s chromosomes lose their ends, the cell usually kills ... discovered how those cells can evade suicide and start down the ... someday may provide new ways to treat cancer. The new ... that losing just one telomere the end of a chromosome ...
Cached Biology News:Are we trading energy conservation for toxic air emissions? 2BioScience tip sheet, October 2008 2BioScience tip sheet, October 2008 3When cells go bad 2When cells go bad 3When cells go bad 4
... a direct antibiotic-based selection system for recombinant ... survival, eliminating the need for costly color ... close to 100% accuracy in recombinant selection. ... robot colony picking. This cloning kit can ...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Alpha-2-AP). [Source:Uniprot/SWISSPROT;Acc:P08697] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... to HDAC8 Regulation of gene ... such as DNA methylation, ATP-dependent chromatin ... histones, which include the dynamic acetylation ... lysine residues present in the tail ...
Biology Products: